Study guide

3.1 Local Anaesthetic Agents, Vasoconstrictors & Injection Techniques

Australian Dental Council ADC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Examination Overview

1.1 ADC Written Examination Structure, Scoring Clusters & Australian Practice Context 1.2 Clinical Scenario Reasoning & Australian Therapeutic Guidelines Alignment

2 Chapter 2: Restorative Dentistry & Fixed Prosthodontics

2.1 Minimal Intervention Dentistry, Caries Risk & Lesion Management 2.2 Direct Restorative Materials, Resin Composites & Dental Amalgam 2.3 Indirect Restorations, Crown Preparation, Veneers & Onlays 2.4 Dental Adhesion, Etch-and-Rinse vs Self-Etch Systems & Hybrid Layer 2.5 Diagnosis & Management of Tooth Wear (Erosion, Attrition, Abrasion, Abfraction)

3 Chapter 3: Dental Pharmacology & Therapeutic Guidelines

3.1 Local Anaesthetic Agents, Vasoconstrictors & Injection Techniques 3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship 3.3 Dental Antibiotic Prescribing, Prophylaxis & Therapeutic Guidelines 3.4 Management of Patients on Anticoagulants & Antiplatelet Therapy 3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management

4 Chapter 4: General Medicine & Medically Compromised Patients

4.1 Dental Office Medical Emergencies, Anaphylaxis & Resuscitation Protocols 4.2 Management of Patients with Cardiovascular, Respiratory & Renal Diseases 4.3 Special Needs Dentistry, Geriatric Care & Dental Management in Pregnancy 4.4 Infective Endocarditis Prophylaxis & Cardiac Risk Assessment

5 Chapter 5: Oral Medicine & Oral Pathology

5.1 Ulcerative, Vesiculobullous & Immune-Mediated Oral Mucosal Diseases 5.2 Oral Potentially Malignant Disorders (OPMDs) & Oral Cancer Screening 5.3 Salivary Gland Disorders, Sialadenitis & Cysts of the Jaws 5.4 Oral Biopsy Indications, Diagnostic Pathways & Specialist Referral

6 Chapter 6: Endodontics

6.1 Pulpal and Periapical Diagnostic Classification & Diagnostic Testing 6.2 Canal Instrumentation, Working Length & Irrigation Protocols 6.3 Root Canal Obturation, Endodontic Retreatment & Failure Analysis 6.4 Endodontic Management of Traumatic Dental Injuries & Vital Pulp Therapy

7 Chapter 7: Oral Surgery

7.1 Surgical & Simple Exodontia Techniques & Intraoperative Complications 7.2 Assessment & Surgical Management of Impacted Third Molars 7.3 Oroantral Communication, Displacement & Trigeminal Nerve Injury Prevention 7.4 Management of Spreading Odontogenic Infections & Fascial Space Abscesses

8 Chapter 8: Paediatric Dentistry & Orthodontics

8.1 Primary Tooth Pulpotomy, Pulpectomy & Stainless Steel Crown Restoration 8.2 Early Childhood Caries, Space Maintenance & Traumatic Primary Dentition 8.3 Malocclusion Classification, Etiology & Interceptive Orthodontic Management 8.4 Non-Pharmacological Behaviour Guidance, Child Protection & Consent

9 Chapter 9: Periodontics

9.1 2018 Periodontal Staging, Grading & Risk Factor Assessment 9.2 Subgingival Debridement, Plaque Control & Antimicrobial Adjuncts 9.3 Periodontal Surgical Flaps, Regenerative Therapy & Furcation Management 9.4 Supportive Periodontal Care, Maintenance Protocols & Risk Re-evaluation

10 Chapter 10: Preventive Dentistry

10.1 Caries Risk Assessment Models (CAMBRA) & Personalised Prevention 10.2 Fluoride Mechanisms, Topical Applications & Community Fluoridation 10.3 Dietary Counselling, Stephan Curve Dynamics & Erosion Prevention 10.4 Pit and Fissure Sealants, Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)

11 Chapter 11: Dental Emergencies

11.1 Emergency Management of Severe Odontogenic Pain & Acute Irreversible Pulpitis 11.2 Acute Management of Avulsed, Luxated & Fractured Permanent Teeth 11.3 Diagnosis, Differentiation & Treatment of Cracked Tooth Syndrome 11.4 Emergency Management of Post-Extraction Hemorrhage & Acute Abscesses

12 Chapter 12: Pain & Behaviour Management

12.1 Assessment & Management of Dental Anxiety, Phobia & Dental Fear 12.2 Nitrous Oxide Inhalation Sedation & Intravenous Sedation Guidelines 12.3 Diagnosis & Management of Temporomandibular Disorders & Chronic Facial Pain 12.4 Informed Consent, Patient Autonomy, Ethics & Professional Boundaries

13 Chapter 13: Removable Prosthodontics

13.1 Complete Denture Design, Impression Techniques & Maxillomandibular Relations 13.2 Removable Partial Denture Design, Surveying, Clasping & RPI System 13.3 Post-Insertion Problems, Sore Spots, Relining & Rebase Procedures 13.4 Denture Stomatitis, Tissue Conditioning & Pre-Prosthetic Surgery

14 Chapter 14: Dental Radiography & Imaging

14.1 Radiation Physics, ALARA Principles, Shielding & Dose Reduction 14.2 Intraoral Radiographic Techniques, Positioning & Geometry 14.3 Radiographic Interpretation, Normal Anatomical Landmarks & Artifacts

15 Chapter 15: Infection Prevention & Control

15.1 Standard & Transmission-Based Precautions in Dental Practice 15.2 Instrument Reprocessing, Autoclaving & Sterilisation Monitoring 15.3 Dental Unit Waterlines, Waste Management & Occupational Exposure Protocols

16 Chapter 16: Dental Implants & Peri-Implant Diseases

16.1 Patient Selection, Bone Density, Anatomic Constraints & Prosthetic Planning 16.2 Peri-Implant Anatomy, Hygiene Protocols & Maintenance Monitoring 16.3 Diagnosis, Risk Factors & Management of Peri-Implant Diseases

3.1 Local Anaesthetic Agents, Vasoconstrictors & Injection Techniques

Key Takeaways Explain This Topic AI

Amide local anaesthetics (lignocaine, articaine, prilocaine, mepivacaine, bupivacaine) are metabolised primarily in the liver, except articaine which undergoes 90-95% plasma carboxylesterase hydrolysis.

Maximum recommended dose (MRD) of 2% lignocaine with 1:80,000 adrenaline is 4.4 mg/kg (absolute maximum 300 mg in Australia), equating to approximately 3.1 cartridges (2.2 mL) for a 70 kg adult.

Articaine 4% is associated with a higher incidence of prolonged paresthesia when used for inferior alveolar nerve blocks (IANB); it is primarily indicated for buccal infiltration in maxillary and mandibular anterior/premolar regions.

Prilocaine 3% with felypressin is contraindicated in pregnancy due to the oxytocic potential of felypressin, and in patients with idiopathic or hereditary methaemoglobinaemia.

Local Anaesthetic Systemic Toxicity (LAST) presents with initial CNS excitation (tinnitus, metallic taste, seizures) followed by CNS and cardiovascular depression; definitive management requires 20% Intralipid emulsion therapy.

Last updated: August 2026

3.1 Local Anaesthetic Agents, Vasoconstrictors & Injection Techniques

Local anaesthesia forms the cornerstone of pain control in clinical dentistry. In Australian dental practice, practitioners must possess a thorough understanding of local anaesthetic (LA) pharmacology, vasoconstrictor interactions, dosage calculations based on Australian standard 2.2 mL cartridges, anatomical injection techniques, and the immediate management of adverse reactions.

Chemical Classification & Pharmacokinetics

Local anaesthetic agents are amphiphilic molecules comprising a lipophilic aromatic ring connected via an intermediate ester or amide chain to a hydrophilic tertiary amine group.

Ester Local Anaesthetics (e.g., Procaine, Benzocaine, Tetracaine): Hydrolysed rapidly in plasma by pseudo-cholinesterase enzymes. Their metabolic product, para-aminobenzoic acid (PABA), carries a relatively high risk of IgE-mediated allergic reactions. Ester agents are rarely used for parenteral injection in contemporary Australian dental practice, though Benzocaine remains in topical formulations.

Amide Local Anaesthetics (e.g., Lignocaine/Lidocaine, Articaine, Prilocaine, Mepivacaine, Bupivacaine): Biotransformed primarily by hepatic cytochrome P450 enzymes. True allergic reactions to amides are extremely rare; hypersensitivity manifestations are usually attributable to the preservative sodium metabisulfite added to adrenaline-containing formulations. +---------------------------------------------------------------------------------------------------+

  • | LOCAL ANAESTHETIC MOLECULAR STRUCTURE |
  • | |
  • | Lipophilic Aromatic Ring =====> Intermediate Chain (Ester/Amide) =====> Hydrophilic Amine |
  • +---------------------------------------------------------------------------------------------------+
  • Mechanism of Action

Local anaesthetics reversibly block voltage-gated sodium channels ( N a v 1.5 Na_v1.5 N a v ​ 1.5 and related subtypes) along the internal membrane surface of nerve axons. By binding to specific receptors within the sodium channel pore, LAs prevent influx of sodium ions, thereby inhibiting membrane depolarisation and blocking action potential conduction along unmyelinated C C C fibres (dull pain, temperature) and small myelinated A δ A\delta A δ fibres (sharp, acute pain).

Pharmacological Profiles of Dental Local Anaesthetics

In Australia, local anaesthetics are supplied in 2.2 mL cartridges . The specific concentration and vasoconstrictor ratios dictate maximum dosage and clinical application.

  • Agent Concentration Vasoconstrictor pKa Onset (min) Half-Life ( t 1 / 2 t_{1/2} t 1/2 ​ ) Primary Elimination
  • Lignocaine 2% (20 mg/mL) Adrenaline 1:80,000 (12.5 µg/mL) 7.9 2 – 4 90 – 120 min Hepatic (CYP1A2 / CYP3A4)

Articaine 4% (40 mg/mL) Adrenaline 1:100,000 (10 µg/mL) or 1:200,000 (5 µg/mL) 7.8 1 – 3 20 – 30 min Plasma Carboxylesterase (90-95%)

  • Prilocaine 3% (30 mg/mL) Felypressin 0.03 IU/mL 7.9 2 – 4 90 min Hepatic & Renal
  • Mepivacaine 3% (30 mg/mL) Plain (No vasoconstrictor) 7.6 1.5 – 2 110 min Hepatic
  • Bupivacaine 0.5% (5 mg/mL) Adrenaline 1:200,000 (5 µg/mL) 8.1 5 – 10 210 min Hepatic
  • Key Agent Characteristics

Lignocaine (Lidocaine) 2% with 1:80,000 Adrenaline : Considered the gold standard reference agent in Australian dentistry. Provides reliable pulpal anaesthesia for 60 minutes and soft tissue anaesthesia for 3–5 hours.

Articaine 4% with Adrenaline : Contains a thiophene ring enhancing lipid solubility and tissue diffusion. Uniquely metabolised predominantly in blood plasma by esterases (90-95%), yielding an exceptionally short half-life (~20 minutes) and reduced systemic toxicity cumulative risk. Excellent for maxillary and mandibular infiltration. However, due to reports of persistent paresthesia (predominantly involving the lingual nerve), many Australian guidelines advise caution when selecting 4% formulations for deep nerve blocks (such as the Inferior Alveolar Nerve Block).

Prilocaine 3% with Felypressin : Felypressin is a synthetic analogue of vasopressin that acts on vascular smooth muscle V 1 V_1 V 1 ​ receptors without significant cardiac β 1 \beta_1 β 1 ​ stimulation. Recommended when adrenaline is strictly contraindicated. Metabolites include o-toluidine , which can induce oxidation of haemoglobin to methaemoglobin.

Mepivacaine 3% Plain : Low vasodilatory property, making it suitable for short procedures where a vasoconstrictor is undesirable.

Bupivacaine 0.5% : High protein binding (95%) and lipid solubility confer long-acting pulpal ( up to 1.5–2 hours) and soft-tissue anaesthesia (up to 8–12 hours), ideal for post-operative pain control in extensive surgical procedures.

Maximum Recommended Dosage (MRD) Calculations

Dosage calculations must be performed on a milligram-per-kilogram (mg/kg) basis, taking into account the patient's lean body mass and maximum ceiling limits defined by Australian Therapeutic Guidelines.

Standard Australian Cartridge Contents (2.2 mL Volume)

2% Solution = 20 mg/mL × \times × 2.2 mL = 44 mg agent per cartridge.

3% Solution = 30 mg/mL × \times × 2.2 mL = 66 mg agent per cartridge.

4% Solution = 40 mg/mL × \times × 2.2 mL = 88 mg agent per cartridge.

0.5% Solution = 5 mg/mL × \times × 2.2 mL = 11 mg agent per cartridge. CALCULATION FORMULA:

  • 1. Patient Weight (kg) x Agent MRD (mg/kg) = Maximum Allowable Dose (mg)
  • 2. Compare with Absolute Maximum Ceiling Limit (choose lower value)
  • 3. Maximum Allowable Dose (mg) / mg per 2.2 mL Cartridge = Maximum Cartridges
  • Agent Dosage Thresholds (Australian Therapeutic Guidelines)

Lignocaine (with Adrenaline) : 4.4 mg/kg; absolute maximum cap of 300 mg (or up to 400-500 mg under strict medical guidelines; standard Australian dental cap is 300 mg).

Example calculation for a 70 kg adult :

70 kg × 4.4 mg/kg = 308 mg 70\text{ kg} \times 4.4\text{ mg/kg} = 308\text{ mg} 70 kg × 4.4 mg/kg = 308 mg .

Apply 300 mg maximum cap limit.

300 mg ÷ 44 mg/cartridge = 6.81 cartridges 300\text{ mg} \div 44\text{ mg/cartridge} = 6.81\text{ cartridges} 300 mg ÷ 44 mg/cartridge = 6.81 cartridges . (Safely rounded down to 6.5 cartridges ).

Articaine (with Adrenaline) : 7.0 mg/kg; absolute maximum cap of 500 mg .

Example for a 70 kg adult :

70 kg × 7.0 mg/kg = 490 mg 70\text{ kg} \times 7.0\text{ mg/kg} = 490\text{ mg} 70 kg × 7.0 mg/kg = 490 mg .

490 mg ÷ 88 mg/cartridge = 5.56 cartridges 490\text{ mg} \div 88\text{ mg/cartridge} = 5.56\text{ cartridges} 490 mg ÷ 88 mg/cartridge = 5.56 cartridges ( 5.5 cartridges ).

Prilocaine (with Felypressin) : 6.0 mg/kg; absolute maximum cap of 400 mg .

Example for a 70 kg adult :

70 kg × 6.0 mg/kg = 420 mg → 70\text{ kg} \times 6.0\text{ mg/kg} = 420\text{ mg} \rightarrow 70 kg × 6.0 mg/kg = 420 mg → Capped at 400 mg.

400 mg ÷ 66 mg/cartridge = 6.06 cartridges 400\text{ mg} \div 66\text{ mg/cartridge} = 6.06\text{ cartridges} 400 mg ÷ 66 mg/cartridge = 6.06 cartridges ( 6.0 cartridges ).

Vasoconstrictors in Dental Local Anaesthesia

Vasoconstrictors are included in local anaesthetics to offset intrinsic vasodilation, prolong duration of action, reduce systemic absorption/toxicity, and enhance local haemostasis.

Adrenaline (Epinephrine)

Acts on α 1 \alpha_1 α 1 ​ receptors (vasoconstriction of skin and mucosal blood vessels), β 1 \beta_1 β 1 ​ receptors (increased heart rate and myocardial contractility), and β 2 \beta_2 β 2 ​ receptors (bronchodilation and peripheral vasodilation in skeletal muscle).

Healthy Adult Maximum Dose : 0.2 mg of adrenaline per appointment.

In 1:80,000 adrenaline (12.5 µg/mL), 2.2 mL contains 27.5 µg (0.0275 mg). Max cartridges based on adrenaline = 0.2 / 0.0275 = 7.27 cartridges 0.2 / 0.0275 = 7.27\text{ cartridges} 0.2/0.0275 = 7.27 cartridges .

Cardiovascular Compromised Maximum Dose (ASA III/IV) : 0.04 mg (40 µg) of adrenaline per appointment.

Restricts 1:80,000 adrenaline to a maximum of 1.4 cartridges (approx 1.5 cartridges) or 1:100,000 to 1.8 cartridges .

Absolute & Relative Contraindications to Vasoconstrictors

Uncontrolled Hyperthyroidism / Thyrotoxicosis : Risk of severe thyroid storm and malignant arrhythmias (Absolute Contraindication for adrenaline).

Recent Myocardial Infarction (<6 months) or Unstable Angina : High risk of re-infarction or fatal arrhythmia (Absolute Contraindication for adrenaline).

Non-Selective Beta-Blockers (e.g., Propranolol): Unopposed α 1 \alpha_1 α 1 ​ stimulation leads to severe hypertension accompanied by compensatory reflex bradycardia.

Tricyclic Antidepressants (TCAs) (e.g., Amitriptyline): Inhibit reuptake of noradrenaline, potentiating adrenaline effect 2- to 4-fold.

Sulfite Hypersensitivity : Sodium metabisulfite is used as an antioxidant in adrenaline formulations. Patients with true bisulfite allergies must receive plain LAs (e.g., Mepivacaine 3% plain).

Injection Techniques & Clinical Efficacy

Inferior Alveolar Nerve Block (IANB) : Targets the inferior alveolar nerve prior to entry into the mandibular foramen. Landmarks: coronoid notch, pterygomandibular raphe, mandibular occlusal plane (10 mm above). Aspiration in 2 planes is imperative (high intravascular injection incidence ~10-15%).

Gow-Gates Technique : True mandibular nerve block targeting the anteromedial border of the condylar neck, below the insertion of the lateral pterygoid muscle. Anaesthetises V3 branches (IAN, lingual, mylohyoid, buccal, auriculotemporal). Higher success rate and lower intravascular aspiration rate (~2%) compared to traditional IANB.

Vazirani-Akinosi (Closed-Mouth) Technique : Indicated when patient presentation includes severe trismus. Target is the pterygomandibular space at the level of the mucogingival junction of the maxillary molars.

Mental / Incisive Nerve Block : Targets mental foramen adjacent to mandibular premolars. Does not anaesthetise lingual soft tissues.

Articaine Buccal Infiltration in Mandibular Molars : Due to high lipid solubility, Articaine 4% buccal infiltration provides pulpal anaesthesia in mandibular first molars comparable to IANB in adult patients, serving as an effective primary or supplemental technique.

  • Complications & Toxicity Management
  • Local Anaesthetic Systemic Toxicity (LAST)

LAST occurs secondary to accidental intravascular injection or severe overdose resulting in plasma levels exceeding toxic thresholds. +---------------------------------------------------------------------------------------------------+

  • | LAST CLINICAL PROGRESSION STAGES |
  • | |
  • | Initial CNS Excitation ====> CNS Depression =====> Cardiovascular Collapse |
  • | - Metallic taste - Slurred speech - Severe hypotension |
  • | - Perioral numbness - Loss of consciousness - Ventricular arrhythmias |
  • | - Tinnitus & tremors - Generalized seizures - Cardiac arrest / Asystole |
  • +---------------------------------------------------------------------------------------------------+
  • Management of LAST Protocol

Stop Administration immediately and call for emergency assistance (000 in Australia).

Maintain Airway : Administer 100% oxygen, prevent hypoxia and hypercapnia (which worsen toxicity).

Control Seizures : Administer intravenous Benzodiazepines (e.g., Midazolam 2.5–5 mg IV/IM).

Lipid Emulsion Therapy : Administer 20% Intralipid : Bolus dose 1.5 mL/kg 1.5\text{ mL/kg} 1.5 mL/kg IV over 1 minute, followed by continuous infusion of 0.25 mL/kg/min 0.25\text{ mL/kg/min} 0.25 mL/kg/min to scavenge lipophilic local anaesthetic from circulation ("lipid sink" mechanism).

Methaemoglobinaemia

Associated primarily with Prilocaine (and high-dose Benzocaine). Metabolic conversion of haemoglobin to methaemoglobin ( F e 3 + Fe^{3+} F e 3 + state) impairs oxygen-carrying capacity. Cyanosis unresponsive to supplemental oxygen occurs when methaemoglobin exceeds 15-20%. Treatment: Intravenous Methylene Blue 1–2 mg/kg over 5 minutes.

Loading diagram... Local Anaesthetic Systemic Toxicity (LAST) Emergency Protocol